OverviewSuggest Edit

BridgeBio is a a clinical-stage bioteccompany focused on discovering and developing drugs for patients with grievous genetic diseases. BridgeBio has built a portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology. The drugs are in various phases of development, from pre-clinical to late-stage.

TypePublic
Founded2014
HQPalo Alto, CA, US
Websitebridgebio.com

Latest Updates

Employees (est.) (Dec 2019)248(+64%)
Job Openings55
Revenue (FY, 2020)$8.2 M(-79%)
Share Price (Jun 2021)$58(-1%)
Cybersecurity ratingBMore

Key People/Management at BridgeBio

Neil Kumar

Neil Kumar

Chief Executive Officer, Director
Charles Homcy

Charles Homcy

Chairman of Pharmaceuticals, Lead Director
Uma Sinha

Uma Sinha

Chief Scientific Officer
Brian C. Stephenson

Brian C. Stephenson

Chief Financial Officer
Richard Scheller

Richard Scheller

Chairman of Research & Development, Director
Eric Aguiar

Eric Aguiar

Director
Show more

BridgeBio Office Locations

BridgeBio has an office in Palo Alto
Palo Alto, CA, US (HQ)
421 Kipling St
Show all (1)

BridgeBio Financials and Metrics

BridgeBio Revenue

BridgeBio's revenue was reported to be $8.25 m in FY, 2020
USD

Revenue (Q1, 2021)

462.0k

Net income (Q1, 2021)

(171.1m)

EBIT (Q1, 2021)

(167.5m)

Market capitalization (4-Jun-2021)

8.6b

Closing stock price (4-Jun-2021)

58.0

Cash (31-Mar-2021)

471.2m

EV

8.3b
BridgeBio's current market capitalization is $8.6 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

40.6m8.2m

General and administrative expense

13.3m43.6m94.4m145.7m

R&D expense

30.6m140.1m209.9m337.0m

Operating expense total

43.9m183.7m304.3m482.7m
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

26.7m8.1m462.0k

General and administrative expense

23.5m34.3m38.0m36.0m45.4m

R&D expense

55.3m68.2m86.6m92.1m122.6m

Operating expense total

78.8m102.5m124.6m128.1m168.0m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

92.0m436.1m363.8m356.1m

Prepaid Expenses

5.1m9.1m22.6m35.7m

Current Assets

97.1m445.2m568.6m642.8m

PP&E

440.0k1.6m5.6m20.3m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

112.4m414.0m757.0m540.9m367.0m471.2m

Prepaid Expenses

22.1m19.8m21.0m26.7m25.5m

Current Assets

558.2m925.0m861.9m745.4m945.1m

PP&E

3.0m15.8m15.6m16.2m22.8m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(43.8m)(169.5m)(288.6m)(505.5m)

Depreciation and Amortization

260.0k245.0k

Accounts Payable

1.6m16.7m(4.7m)(735.0k)

Cash From Operating Activities

(40.5m)(136.6m)(253.6m)(399.7m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(204.4m)(104.1m)(240.3m)(370.5m)(171.1m)

Depreciation and Amortization

618.0k

Accounts Payable

(3.2m)4.2m4.0m547.0k1.8m

Cash From Operating Activities

(177.4m)(83.9m)(171.8m)(303.5m)(150.8m)
USDFY, 2017

Financial Leverage

-1.7 x
Show all financial metrics

BridgeBio Acquisitions / Subsidiaries

Company NameDateDeal Size
Adrenas Therapeutics, Inc.
Aspa Therapeutics, Inc.
BridgeBio Services, Inc.
Calcilytix Therapeutics, Inc.
CoA Therapeutics, Inc.
Dermecular Therapeutics, Inc.
Eidos Therapeutics, Inc.
Ferro Therapeutics, Inc.
Fortify Therapeutics, Inc.
Molecular Skin Therapeutics, Inc.
Show more

BridgeBio Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

BridgeBio Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

BridgeBio Online and Social Media Presence

Embed Graph

BridgeBio News and Updates

BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1

PALO ALTO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced tha…

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement

BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia

- Preclinical Data for Congenital Adrenal Hyperplasia and Canavan Disease Programs Shared at American Society of Gene & Cell Therapy Annual Meeting, Enabling Anticipated Clinical Trials This Year - Preclinical Data for Congenital Adrenal Hyperplasia and Canavan Disease Programs Shared at America…

BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update

–Received U.S. Food and Drug Administration (FDA) approval for NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A

BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions

PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic applications for patients, with a …

BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers

TORRANCE, Calif. and PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven diseases and cancers …
Show more

BridgeBio Blogs

Sr. Manager/Associate Director, Drug Substance Development

The post Sr. Manager/Associate Director, Drug Substance Development appeared first on BridgeBio.

Sr. Manager/Associate Director, Analytical Development

The post Sr. Manager/Associate Director, Analytical Development appeared first on BridgeBio.

Director, Formulation Development

The post Director, Formulation Development appeared first on BridgeBio.

Business Operations Manager

The post Business Operations Manager appeared first on BridgeBio.

Director/Senior Director, CMC Project Management

The post Director/Senior Director, CMC Project Management appeared first on BridgeBio.

Preclinical Associate Scientist

The post Preclinical Associate Scientist appeared first on BridgeBio.
Show more

BridgeBio Frequently Asked Questions

  • When was BridgeBio founded?

    BridgeBio was founded in 2014.

  • Who are BridgeBio key executives?

    BridgeBio's key executives are Neil Kumar, Charles Homcy and Uma Sinha.

  • How many employees does BridgeBio have?

    BridgeBio has 248 employees.

  • What is BridgeBio revenue?

    Latest BridgeBio annual revenue is $8.2 m.

  • What is BridgeBio revenue per employee?

    Latest BridgeBio revenue per employee is $33.3 k.

  • Who are BridgeBio competitors?

    Competitors of BridgeBio include Hartington Pharmaceutical, Biogenes and Terns Pharmaceuticals.

  • Where is BridgeBio headquarters?

    BridgeBio headquarters is located at 421 Kipling St, Palo Alto.

  • Where are BridgeBio offices?

    BridgeBio has an office in Palo Alto.

  • How many offices does BridgeBio have?

    BridgeBio has 1 office.